RxDoctor Payments Data

Erica Webb

Psychiatric/Mental Health · Georgetown, KYNPI 1265162390

Payments from drug & device makers

$1,078in general payments, 2019–2025

Across 51 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$737
  • Neurocrine Biosciences, Inc.$159
  • Johnson & Johnson$67
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$50
  • Boston Scientific$20
  • Corium, LLC$16
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$1,078100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,078 in reported general payments places this provider in the 55th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$9,602
Medicare patients
21
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole13$35,970
VraylarCariprazine Hcl20$31,503
Adderall XrDextroamphetamine/Amphetamine11$2,272
Aripiprazole17$1,098
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine18$931
Carbamazepine13$673
Bupropion XlBupropion Hcl37$638
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine22$606
Quetiapine Fumarate ErQuetiapine Fumarate20$529
Lamotrigine45$452
Methylphenidate Hcl23$416
Buspirone Hcl53$376
Duloxetine Hcl16$262
Fluoxetine Hcl42$260
Sertraline Hcl51$234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$737$31,50320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Georgetown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →